scopolamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2424 51-34-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • scopolamine
  • scopolamine hydrobromide
  • hyoscine
  • levo-duboisine
  • scopoderm
  • scopolamine hydrochloride
  • scopolamine HCl
An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic.
  • Molecular weight: 303.36
  • Formula: C17H21NO4
  • CLOGP: 0.09
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 62.30
  • ALOGS: -1.66
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.90 mg O
0.90 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 666.67 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 27 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1979 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mydriasis 102.67 15.16 43 7967 11913 63469099
Anticholinergic syndrome 90.31 15.16 26 7984 2356 63478656
Akathisia 72.23 15.16 31 7979 9115 63471897
Vomiting 37.94 15.16 155 7855 559462 62921550
Product adhesion issue 37.27 15.16 16 7994 4703 63476309
High density lipoprotein decreased 33.65 15.16 12 7998 2158 63478854
Neutrophil count increased 29.61 15.16 21 7989 16506 63464506
Infectious mononucleosis 27.36 15.16 10 8000 1929 63479083
Application site rash 24.89 15.16 10 8000 2488 63478524
Progressive multiple sclerosis 24.04 15.16 8 8002 1170 63479842
Vision blurred 23.70 15.16 42 7968 91882 63389130
Nausea 23.09 15.16 185 7825 854286 62626726
Differential white blood cell count abnormal 22.90 15.16 7 8003 779 63480233
Red cell distribution width increased 22.71 15.16 15 7995 10509 63470503
Hallucination 22.46 15.16 31 7979 54786 63426226
Tachyarrhythmia 22.30 15.16 11 7999 4439 63476573
Suicidal ideation 20.78 15.16 32 7978 62389 63418623
Blood lactic acid increased 20.07 15.16 12 7998 7074 63473938
Arthropathy 19.80 15.16 3 8007 234789 63246223
Tachycardia 19.68 15.16 45 7965 118111 63362901
Cytarabine syndrome 19.52 15.16 4 8006 85 63480927
Salivary hypersecretion 19.19 15.16 12 7998 7654 63473358
Drug ineffective 19.06 15.16 68 7942 1044697 62436315
Application site reaction 19.00 15.16 6 8004 744 63480268
Long QT syndrome congenital 18.86 15.16 4 8006 101 63480911
Joint swelling 18.68 15.16 9 8001 327657 63153355
Application site erythema 18.58 15.16 10 8000 4825 63476187
Alopecia 18.16 15.16 10 8000 337526 63143486
Colitis 17.75 15.16 26 7984 48502 63432510
Hyperkinesia 17.60 15.16 7 8003 1697 63479315
Cardiac output decreased 17.47 15.16 6 8004 966 63480046
Small intestinal obstruction 17.27 15.16 16 7994 18321 63462691
Intra-abdominal haematoma 17.21 15.16 7 8003 1798 63479214
Disorientation 17.20 15.16 23 7987 39429 63441583
Blood alkaline phosphatase increased 17.15 15.16 24 7986 42943 63438069
Antipsychotic drug level above therapeutic 17.05 15.16 6 8004 1037 63479975
Systemic lupus erythematosus 16.87 15.16 3 8007 208915 63272097
Abdominal pain 16.51 15.16 77 7933 293379 63187633
Porphyria acute 16.34 15.16 6 8004 1171 63479841
Drug monitoring procedure incorrectly performed 16.13 15.16 4 8006 204 63480808
Dehydration 15.84 15.16 53 7957 173301 63307711
Delirium 15.56 15.16 25 7985 50516 63430496
Infusion related reaction 15.17 15.16 6 8004 245515 63235497

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count increased 79.89 17.83 45 6088 17101 34933697
Prescription drug used without a prescription 76.05 17.83 24 6109 2130 34948668
Failure to suspend medication 64.21 17.83 15 6118 423 34950375
Neuroleptic malignant syndrome 54.98 17.83 36 6097 17898 34932900
Antipsychotic drug level increased 51.81 17.83 21 6112 3844 34946954
White blood cell count increased 50.29 17.83 48 6085 41103 34909695
Wrong patient received product 41.08 17.83 16 6117 2638 34948160
Toxicity to various agents 40.05 17.83 100 6033 200262 34750536
Accidental death 38.70 17.83 15 6118 2441 34948357
Antipsychotic drug level decreased 34.52 17.83 11 6122 1006 34949792
Platelet count decreased 34.26 17.83 69 6064 119648 34831150
Salivary hypersecretion 33.13 17.83 20 6113 8624 34942174
Ideas of reference 32.61 17.83 6 6127 49 34950749
White blood cell count decreased 32.20 17.83 59 6074 95386 34855412
Platelet count increased 31.34 17.83 20 6113 9506 34941292
Confusional state 30.93 17.83 74 6059 144086 34806712
Lymphocyte count decreased 30.72 17.83 28 6105 22594 34928204
Differential white blood cell count abnormal 30.63 17.83 11 6122 1448 34949350
Vomiting 30.53 17.83 104 6029 247517 34703281
Pneumonia aspiration 28.61 17.83 36 6097 41867 34908931
Neutrophil count decreased 27.38 17.83 39 6094 51065 34899733
Hallucination 27.14 17.83 39 6094 51459 34899339
Red blood cell elliptocytes present 26.65 17.83 6 6127 143 34950655
Seizure 24.85 17.83 56 6077 104801 34845997
Incision site pain 24.67 17.83 10 6123 1828 34948970
Portal tract inflammation 24.33 17.83 5 6128 76 34950722
Incorrect product dosage form administered 24.32 17.83 6 6127 214 34950584
Pneumoconiosis 23.98 17.83 6 6127 227 34950571
Serotonin syndrome 23.85 17.83 23 6110 19910 34930888
Mydriasis 23.32 17.83 15 6118 7222 34943576
Schizophrenia 23.20 17.83 16 6117 8650 34942148
Agitation 22.60 17.83 38 6095 57361 34893437
Product adhesion issue 22.50 17.83 9 6124 1591 34949207
Volvulus 22.32 17.83 9 6124 1623 34949175
Drug ineffective 21.87 17.83 29 6104 456722 34494076
Body temperature increased 20.70 17.83 20 6113 17348 34933450
Mental impairment 20.69 17.83 16 6117 10306 34940492
Mean cell volume decreased 20.19 17.83 8 6125 1380 34949418
Convulsive threshold lowered 19.01 17.83 6 6127 532 34950266
Hepatic steatosis 17.96 17.83 19 6114 18343 34932455

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count increased 113.79 14.64 65 12029 29331 79702963
Mydriasis 84.76 14.64 45 12049 17598 79714696
Anticholinergic syndrome 78.82 14.64 27 12067 3584 79728710
Neuroleptic malignant syndrome 68.58 14.64 46 12048 27513 79704781
Akathisia 67.04 14.64 35 12059 13224 79719070
Vomiting 62.68 14.64 232 11862 665596 79066698
Failure to suspend medication 59.88 14.64 14 12080 460 79731834
White blood cell count increased 56.58 14.64 63 12031 74570 79657724
Differential white blood cell count abnormal 55.15 14.64 18 12076 2059 79730235
Antipsychotic drug level increased 52.38 14.64 23 12071 5934 79726360
Wrong patient received product 44.43 14.64 19 12075 4599 79727695
Hallucination 41.81 14.64 58 12036 85687 79646607
Lymphocyte count decreased 41.24 14.64 43 12051 47246 79685048
Salivary hypersecretion 38.43 14.64 25 12069 14199 79718095
Accidental death 35.90 14.64 16 12078 4275 79728019
Antipsychotic drug level above therapeutic 35.67 14.64 13 12081 2067 79730227
Seizure 35.16 14.64 84 12010 188750 79543544
Drug ineffective 34.73 14.64 70 12024 1080843 78651451
Platelet count decreased 34.54 14.64 85 12009 194579 79537715
White blood cell count decreased 34.24 14.64 83 12011 188205 79544089
Neutrophil count decreased 33.60 14.64 55 12039 93904 79638390
Incision site pain 31.78 14.64 13 12081 2817 79729477
Antipsychotic drug level decreased 30.06 14.64 10 12084 1214 79731080
Confusional state 29.92 14.64 111 11983 317886 79414408
High density lipoprotein decreased 28.54 14.64 14 12080 4641 79727653
Arthralgia 28.36 14.64 27 12067 571776 79160518
Constipation 27.63 14.64 100 11994 282950 79449344
Agitation 27.40 14.64 52 12042 99663 79632631
Ideas of reference 26.73 14.64 6 12088 164 79732130
Pneumonia aspiration 26.41 14.64 41 12053 66926 79665368
Platelet count increased 26.33 14.64 24 12070 22382 79709912
Red blood cell elliptocytes present 25.41 14.64 6 12088 206 79732088
Volvulus 25.24 14.64 11 12083 2785 79729509
Tachycardia 24.79 14.64 71 12023 177697 79554597
Pneumoconiosis 24.47 14.64 6 12088 242 79732052
Serotonin syndrome 24.28 14.64 32 12062 44995 79687299
Incorrect product dosage form administered 23.20 14.64 6 12088 301 79731993
Portal tract inflammation 22.66 14.64 5 12089 126 79732168
Blood alkaline phosphatase increased 22.39 14.64 37 12057 63627 79668667
Progressive multiple sclerosis 22.34 14.64 8 12086 1209 79731085
Joint swelling 22.23 14.64 8 12086 288638 79443656
Mental impairment 21.61 14.64 20 12074 19016 79713278
Dyskinesia 21.38 14.64 30 12064 44743 79687551
Convulsive threshold lowered 20.35 14.64 7 12087 940 79731354
Rheumatoid arthritis 19.38 14.64 4 12090 208466 79523828
Red cell distribution width increased 19.24 14.64 17 12077 15225 79717069
Application site erythema 18.96 14.64 11 12083 5099 79727195
Antipsychotic drug level below therapeutic 18.52 14.64 7 12087 1231 79731063
Product administered to patient of inappropriate age 18.11 14.64 11 12083 5542 79726752
Cytarabine syndrome 18.08 14.64 4 12090 102 79732192
Haemoglobin decreased 17.99 14.64 74 12020 222045 79510249
Hepatic steatosis 17.60 14.64 25 12069 37713 79694581
Arthropathy 17.31 14.64 3 12091 177108 79555186
Muscle rigidity 17.19 14.64 18 12076 19864 79712430
Musculoskeletal stiffness 17.02 14.64 3 12091 175005 79557289
Infusion related reaction 16.70 14.64 7 12087 230230 79502064
Mean cell volume decreased 16.65 14.64 10 12084 4937 79727357
Somnolence 16.59 14.64 76 12018 238905 79493389
Dehydration 16.54 14.64 78 12016 248109 79484185
Long QT syndrome congenital 16.52 14.64 4 12090 153 79732141
Drug intolerance 16.22 14.64 10 12084 264109 79468185
Delirium 16.11 14.64 38 12056 84589 79647705
Body temperature increased 15.87 14.64 26 12068 44394 79687900
Electrocardiogram QT prolonged 15.51 14.64 39 12055 90347 79641947
Alopecia 15.29 14.64 8 12086 231347 79500947
Swelling 15.07 14.64 7 12087 216704 79515590
Hallucination, auditory 14.87 14.64 17 12077 20676 79711618
Abdominal discomfort 14.70 14.64 10 12084 250717 79481577
Apnoea 14.67 14.64 13 12081 11691 79720603

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A04AD01 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
ATC A04AD51 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
ATC N05CM05 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Other hypnotics and sedatives
ATC S01FA02 SENSORY ORGANS
OPHTHALMOLOGICALS
MYDRIATICS AND CYCLOPLEGICS
Anticholinergics
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D009184 Mydriatics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50513 mydriatics
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:53784 antispasmodics
CHEBI has role CHEBI:60807 anaesthestic adjuvant
CHEBI has role CHEBI:60809 adjuvants

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Irritable bowel syndrome indication 10743008 DOID:9778
Peptic ulcer indication 13200003 DOID:750
Motion sickness indication 37031009 DOID:2951
Dilated pupil indication 37125009
Cough indication 49727002
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Cycloplegia indication 68158006 DOID:10033
Nasal congestion indication 68235000
Iridocyclitis indication 77971008
Common cold indication 82272006 DOID:10459
Posterior synechiae indication 111512005
Uveitis indication 128473001 DOID:13141
Prevention of Posterior Synechiae indication
Perioperative Mydriasis indication
Prevention of Motion Sickness indication
Prevention of Post-Operative Nausea and Vomiting indication
General anesthesia off-label use 50697003
Excessive salivation off-label use 53827007
Rhinitis off-label use 70076002 DOID:4483
Seasonal allergic rhinitis off-label use 367498001
Brain damage contraindication 2470005
Ocular hypertension contraindication 4210003 DOID:9282
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Disorder of lung contraindication 19829001 DOID:850
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Ventricular tachycardia contraindication 25569003
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypovolemic shock contraindication 39419009
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Paralytic ileus contraindication 55525008 DOID:8442
Heart disease contraindication 56265001 DOID:114
Peptic reflux disease contraindication 57643001
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by phenobarbital contraindication 64921004
Arterial thrombosis contraindication 65198009
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Chronic idiopathic constipation contraindication 82934008
Hiatal hernia contraindication 84089009 DOID:12642
Open-angle glaucoma contraindication 84494001 DOID:1067
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Magnetic resonance imaging contraindication 113091000
Hypoalbuminemia contraindication 119247004
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Myocardial dysfunction contraindication 233928007
Arterial aneurysm contraindication 233981004
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Severe chronic obstructive pulmonary disease contraindication 313299006
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic
pKa2 7.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.86 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 9.40 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 9.37 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.75 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Kd 8.52 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 9.28 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Kd 9.19 CHEMBL
Muscarinic receptor M1 GPCR Ki 9.39 CHEMBL
Muscarinic acetylcholine receptor DM1 GPCR Ki 9.15 CHEMBL
Muscarinic acetylcholine receptor GPCR Ki 10.10 CHEMBL

External reference:

IDSource
4018401 VUID
N0000146728 NUI
D00138 KEGG_DRUG
6533-68-2 SECONDARY_CAS_RN
4018399 VANDF
4018401 VANDF
4018412 VANDF
C0036442 UMLSCUI
CHEBI:16794 CHEBI
CHEMBL1187846 ChEMBL_ID
CHEMBL569713 ChEMBL_ID
DB00747 DRUGBANK_ID
CHEMBL2251240 ChEMBL_ID
CHEMBL1256744 ChEMBL_ID
D012601 MESH_DESCRIPTOR_UI
3000322 PUBCHEM_CID
330 IUPHAR_LIGAND_ID
55-16-3 SECONDARY_CAS_RN
DL48G20X8X UNII
9601 RXNORM
1472 MMSL
5444 MMSL
5445 MMSL
72365 MMSL
d00986 MMSL
001719 NDDF
003458 NDDF
387409009 SNOMEDCT_US
387477005 SNOMEDCT_US
72870001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Transderm Scop HUMAN PRESCRIPTION DRUG LABEL 1 0067-4346 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL NDA 29 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 0378-6470 PATCH 1 mg TRANSDERMAL ANDA 30 sections
Belladonna Alkaloids with Phenobartbital HUMAN PRESCRIPTION DRUG LABEL 4 0440-7183 TABLET 0.01 mg ORAL UNAPPROVED DRUG OTHER 14 sections
scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-2258 SYSTEM 1 mg TRANSDERMAL ANDA 27 sections
Transderm Scop HUMAN PRESCRIPTION DRUG LABEL 1 10019-553 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL NDA 29 sections
Transderm Scop HUMAN PRESCRIPTION DRUG LABEL 1 10019-553 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL NDA 29 sections
Transderm Scop HUMAN PRESCRIPTION DRUG LABEL 1 10019-553 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL NDA 29 sections
Phenohytro HUMAN PRESCRIPTION DRUG LABEL 4 17856-0123 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 18 sections
Phenohytro HUMAN PRESCRIPTION DRUG LABEL 4 17856-0125 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 18 sections
Phenohytro HUMAN PRESCRIPTION DRUG LABEL 4 17856-0125 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 18 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS HUMAN PRESCRIPTION DRUG LABEL 4 17856-0162 ELIXIR 0.01 mg ORAL unapproved drug other 16 sections
Donnatal HUMAN PRESCRIPTION DRUG LABEL 4 17856-0423 ELIXIR 0.01 mg ORAL unapproved drug other 12 sections
RE-PB HYOS ELIXIR HUMAN PRESCRIPTION DRUG LABEL 4 21695-594 ELIXIR 0.01 mg ORAL Unapproved drug other 11 sections
Belladonna Alkaloids with Phenobartbital HUMAN PRESCRIPTION DRUG LABEL 4 21695-890 TABLET 0.01 mg ORAL Unapproved drug other 15 sections
QUADRAPAX HUMAN PRESCRIPTION DRUG LABEL 4 21695-970 ELIXIR 0.01 mg ORAL Unapproved drug other 13 sections
Donnatal HUMAN PRESCRIPTION DRUG LABEL 4 42254-268 TABLET 0.01 mg ORAL Unapproved drug other 15 sections
PHENOBARBITAL WITH BELLADONNA ALKALOIDS HUMAN PRESCRIPTION DRUG LABEL 4 42291-205 ELIXIR 0.01 mg ORAL unapproved drug other 17 sections
Donnatal HUMAN PRESCRIPTION DRUG LABEL 4 42291-245 TABLET 0.01 mg ORAL unapproved drug other 22 sections
Scopolamine Trandermal System HUMAN PRESCRIPTION DRUG LABEL 1 45802-580 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL ANDA 30 sections
Scopolamine Trandermal System HUMAN PRESCRIPTION DRUG LABEL 1 45802-580 PATCH, EXTENDED RELEASE 1 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50090-5349 PATCH 1 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50090-5349 PATCH 1 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50742-505 PATCH, EXTENDED RELEASE 1.50 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50742-505 PATCH, EXTENDED RELEASE 1.50 mg TRANSDERMAL ANDA 30 sections
Scopolamine HUMAN PRESCRIPTION DRUG LABEL 1 50742-505 PATCH, EXTENDED RELEASE 1.50 mg TRANSDERMAL ANDA 30 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-665 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-665 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-666 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-666 ELIXIR 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide Human Prescription Drug Label 4 50742-667 TABLET 0.01 mg ORAL UNAPPROVED DRUG OTHER 20 sections